​

Mineralys Therapeutics (MLYS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MLYS Stock Forecast

Mineralys Therapeutics (MLYS) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $48.00, with a high of $48.00 and a low of $48.00. This represents a 18.34% increase from the last price of $40.56.

$5 $14 $23 $32 $41 $50 High: $48 Avg: $48 Low: $48 Last Closed Price: $40.56

MLYS Stock Rating

Mineralys Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

MLYS Price Target Upside V Benchmarks

TypeNameUpside
StockMineralys Therapeutics18.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$45.00
Last Closing Price$40.56$40.56$40.56
Upside/Downside--10.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25171--9
Sep, 25171--9
Aug, 25261--9
Jul, 25261--9
Jun, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2025Seamus FernandezGuggenheim$48.00$15.11217.67%18.34%
Apr 02, 2025Matthew CaufieldH.C. Wainwright$42.00$14.00200.00%3.55%
Apr 02, 2024Richard LawGoldman Sachs$30.00$13.03130.24%-26.04%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2025JefferiesHoldinitialise
May 14, 2025GuggenheimBuyBuyhold
Apr 02, 2025H.C. WainwrightBuyBuyhold
Jul 10, 2024H.C. WainwrightBuyinitialise
Apr 02, 2024Goldman SachsBuyinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.99$-3.66----
Avg Forecast$-2.28$-3.69$-3.85$-3.47$-3.58$-2.03
High Forecast$-1.95$-3.16$-3.83$-2.46$-3.20$-2.03
Low Forecast$-2.61$-3.94$-3.88$-4.74$-4.28$-2.03
Surprise %-12.72%-0.81%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$14.44M$98.83M$245.99M
High Forecast---$14.44M$98.83M$245.99M
Low Forecast---$14.44M$98.83M$245.99M
Surprise %------

Net Income Forecast

$-200M $-170M $-140M $-110M $-80M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-71.90M$-177.81M----
Avg Forecast$-71.90M$-128.43M$-139.38M$-130.42M$-135.28M$-73.46M
High Forecast$-70.55M$-114.45M$-138.52M$-89.17M$-115.81M$-73.46M
Low Forecast$-94.29M$-142.42M$-140.23M$-171.68M$-154.74M$-73.46M
Surprise %-38.44%----

MLYS Forecast FAQ

Is Mineralys Therapeutics stock a buy?

Mineralys Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mineralys Therapeutics is a favorable investment for most analysts.

What is Mineralys Therapeutics's price target?

Mineralys Therapeutics's price target, set by 7 Wall Street analysts, averages $48 over the next 12 months. The price target range spans from $48 at the low end to $48 at the high end, suggesting a potential 18.34% change from the previous closing price of $40.56.

How does Mineralys Therapeutics stock forecast compare to its benchmarks?

Mineralys Therapeutics's stock forecast shows a 18.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Mineralys Therapeutics over the past three months?

  • October 2025: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Mineralys Therapeutics’s EPS forecast?

Mineralys Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.85, marking a 5.19% increase from the reported $-3.66 in 2024. Estimates for the following years are $-3.47 in 2026, $-3.58 in 2027, and $-2.03 in 2028.

What is Mineralys Therapeutics’s revenue forecast?

Mineralys Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $14.44M, followed by $98.83M for 2027, and $245.99M for 2028.

What is Mineralys Therapeutics’s net income forecast?

Mineralys Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-139M, representing a -21.62% decrease from the reported $-178M in 2024. Projections indicate $-130M in 2026, $-135M in 2027, and $-73.462M in 2028.